The influence of imbalance of placental angiogenesis factors on clinical manifestations of the «early» and «last» preeclampsia

The nephrological manifestations of the «early» and «late» pre-eclampsia (PE) in relation comparison with the markers of placental angiogenesis: VEGF and sFlt-1 are presented. It was found that women with «early» PE with gestation age of Me 32 [29; 34] weeks had higher rates of blood pressure (the mean systolic BP was 170 ± 16,8 mm Hg vs. 156 ± 6,56 mm Hg and the mean diastolic BP of 105 ± 8,9 mm Hg vs. 99 ± 6,9 mm Hg). They 4 times more often showed renal dysfunction as manifested by a decrease in the glomerular filtration rate (Ме 70 [51; 80] ml/min) or an increase in serum creatinine (Ме 90 [78; 102] mol/l), 7 times more often developed nephrotic syndrome and a three-fold excess of sFlt-1 as compared with the patients developed a «late» PE-gestation age Me 38 [36; 39] weeks. An inverse correlation was found between GFR and sFlt-1 (rs = –0,42; р = 0,050) and direct correlation between GFR and VEGF (rs = 0,47; р = 0,038) among women with preeclamptic pregnancies. The role of the imbalance of placental angiogenesis markers in the formation of proteinuria, hypertension and renal disfunction are discussed, and the contribution of thrombophilia to the development of the PE is considered.

preeclampsia, glomerular injury, vascular endothelium growth factor (VEGF), soluble fms-like tyrosine kinase 1 receptors (sFlt-1), blood pressure, glomerular filtration rate, proteinuria, podocynuria, преэклампсия, гломерулярное поражение, васкулоэндотелиальный фактор роста (VEGF), растворимая fms-подобная тирозинкиназа 1 (sFlt-1), артериальная гипертензия, скорость клубочковой фильтрации, протеинурия, подоцинурия

1. Боброва Л.А. Поражение почек при наследственных и приобретенных тромбофилиях: Автореф. дис. … канд. мед. наук. М.,2010.

2. Шилов Е.М., Козловская Н.Л., Метелева Н.А. и др. Клинические проявления нефропатии, связанной с антифосфолипидным синдромом, при первичном антифосфолипидном синдроме // Тер. архив. 2003. Т. 75. № 6. С. 22–27.

3. Диагностика и лечение артериальной гипертензии. Российские рекомендации (третий пересмотр) Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов. М., 2008. С. 32.

4. Aita K., Etoh M., Hamada H. et al. Acute and transient podocyte loss and proteinuria in preeclamsia // Nephron. Clin. Practice. 2009. Vol. 112. Р. 65–70.

5. Ballermann B.J. Glomerular endothelial cell differentiation // Kidney Int. 2005. Vol. 67. P. 1668–1671.

6. Baumwell A., Karumanchi S.A. Pre-eclampsia: clinical manifestation and molecular mechanisms // Nephron. Clin. Pract. 2007. Vol. 106. P. 72–81.

7. Bolle G., Patey N., Cazajous G. et al. Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib // Nephrol. Dial. Transplant. 2009. Vol. 24. P. 682–685.

8. Brown M.A., Lindheimer M.D., de Swiet M. et al. The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). (Review) // Hypertens. Pregnancy. 2001 Vol. 20 (1). P. 9–14.

9. Cohen A.W., Burton N.G. Nephrotic syndrome due to preeclamptic nephropathy in hydatidiform mole and coexistent fetus // Obstet. Gynecol. 1979. Vol. 53. P. 130–134.

10. Dekker G.A., de Vries J.I.P., Doelitzsch P.M. et al. Underlying disorders associated with severe early-onset preeclampsia // Am. J. Obstet. Gynecol. 1995. Vol. 173. P. 1042–1048.

11. Eremina V., Jefferson A., Kowalewska J. et al. VEGF inhibition and renal thrombotic microangiopathy // N. Engl. J. Med. 2008. Vol. 358. P. 1129–1139.

12. Eremina V., Sood M., Haigh J. et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases // J. Clin. Invest. 2003. Vol. 111. P. 707–716.

13. Fisher K.A., Ahuja S., Luger A.M. et al. Nephrotic proteinuria with preeclampsia // Am. J. Obstet. Gynecol. 1977. Vol. 129. P. 643–646.

14. Garovic V., Wagner S., Petrovic L. et al. Glomerular expression of nephrin and synaptopodin, but not podocin, is decreased in kidney sections from women with preeclampsia // Nephrol. Dial. Transplant. 2007. Vol. 22. P. 1136–1143.

15. Garovic V.D., Wagner S.J., Turner S.T. Urinary podocyte excretion as a marker for preeclampsia // Am. J. Obst. Gynecol. 2007. Vol. 196. P. 320–327.

16. Henao D., Saleem M.A., Cadavid A.P. Glomerular disturbances in preeclamsia: disruption between glomerular endothelium and podocyte symbiosis // Hypertens. Pregnancy. 2009. Vol. 1. P. 1–11.

17. Hertig A., Watnick S., Strevens H. et al. How should women with pre-eclampsia be followed up? New insights from mechanistic studies // Nature Clin. Pract. Nephrol. 2008. Vol. 4. P. 503–509.

18. Ihle B.U., Long P., Oats J. Early onset preeclampsia: Recognition of underlying renal disease // Br. Med. J. (Clin. Res. Ed.). 1987. Vol. 294. P. 79.

19. James P.R., Nelson-Piercy C. Management of hypertension before, during and after pregnancy // Heart. 2004. Vol. 90. P. 1499–1504.

20. Karumanchi S.A., Maynard S.E., Stillman I.E. et al. Preeclampsia: a renal perspective // Kidney Intern. 2005. Vol. 67. P. 2101–2113.

21. Lafayette R.A., Druzin M., Sibley R. et al. Nature of glomerular disfunction in pre-eclampsia // Kidney Int. 1998. Vol. 54. P. 1240–1249.

22. Lee R.M., Brown M.A., Branch D.W. et al. Anticardiolipin and anti-B2 glycoprotein-I antibodies in preeclampsia // Obstet. Gynecol. 2003. Vol. 102. P. 294 –300.

23. Levine R.J., Maynard S.E., Quan C. et al. Circulating angiogenic factors and the risk of preeclampsia // N. Engl. J. Med. 2004. Vol. 350. P. 672–683.

24. Maynard S.E., Min J.Y., Lim K.H. et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt-1) may contribute to endothelian dysfunction, hypertension, and proteinuria in preeclampsia // J. Clin. Invest. 2003. Vol. 111. P. 649–658.

25. Moran P., Baylis P.H., Lindheimer M.D. et al. Glomerular ultrafiltration in normal and pre-eclamptic pregnancy // J. Am. Soc. Nephrol. 2003. Vol. 14. P. 648–652.

26. Muller-Deile J., Schiffer M. Renal involvement in preeclampsia: similarities to VEGF ablation therapy // J. of Pregnancy. 2011. Vol. 2011. 6 pages. Article ID 176973.

27. Muller-Deile J., Worthman K., Saleem I. et al. The balance of autocrine VEGF-A and VEGF-C determines podocyte survival // Am. J. Physiol – Renal Physiol. 2009. Vol. 297. P. 1656–1667.

28. Noris M., Perico N., Remuzzi G. Mechanisms of disease: pre-eclampsia // Nature Clin. Pract. Nephrol. 2005. Vol. 1 (2). P. 98–114.

29. Poon L.C.Y., Kametas N.A., Maiz N. et al. First trimestre prediction of hypertensive disorders in pregnancy // Hypertension. 2009. Vol. 53. P. 812–818.

30. Powe C.E., Levine R.J., Karumanchi S.A. Preeclampsia, a disease of the maternal endothelium. The role of antiangiogenic factors and implications for later cardiovascular disease // Circulation. 2011. Vol. 123. P. 2856–2869.

31. Saudan P., Brown M.A., Buddle M.L. et al. Does gestational hypertension become pre-eclampsia? // Br. J. Obstet. Gynecol. 1998. Vol. 105. P. 1177–1184.

32. Stillman I.E., Karumanchi S.A. The glomerular injury of preeclampsia // J. Am. Soc. Nephrol. 2007. Vol. 18. P. 2281–2284.

33. Strevens H., Wide-Swensson D., Hansen A. еt al. Glomerular endotheliosis in normal pregnancy and preeclampsia // Br. J. Obst. Gynecol. 2003. Vol. 110. P. 831–836.

34. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy // Am. J. Obstet. Gynecol. 2000. Vol. 183. P. 1–22.